Apoproteins of very low density lipoproteins of plasma from male chronic alcoholics and healthy men serving as controls were investigated. VLDL were delipidated using diethyl ether-ethanol and were separated by polyacrylamide gel electrophoresis. The average relative concentration of apo Cll, Clll1 and Clll2 are investigated. The proportion of apo Cll is reduced, and that of apo Clll increased (particularly Clll1) in male chronic alcoholics compared to the normal and the ratio of apo Clll1 to apo cll was significantly increased. The Cll/Clll1 + Clll2 ratio is highly significantly reduced in patients. Changes in apo Clll1/Cll ratio in relation to hypertriglyceridaemia are envisaged. Furthermore apo Cll is believed to activate and apo Clll to inhibit lipoprotein lipase activity "in vitro".
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein Lipase/Apolipoprotein Cll Gene Polymorphism in Kurdish Patients With Severe Hypertriglyceridemia.
Cureus
October 2023
Department of Medical Chemistry, College of Medicine, University of Duhok, Duhok, IRQ.
Background Polymorphisms in the () and genes have been linked to severe hypertriglyceridemia in several populations. This study investigated the frequency of Hind lllandAva ll polymorphism among Kurdish patients with severe hypertriglyceridemia. Methodology We investigated Hind llland -Ava ll gene polymorphism in a sample of Kurdish patients receiving treatment at Azadi Teaching Hospital in Duhok, Kurdistan Region, Iraq.
View Article and Find Full Text PDFHow We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.
Curr Oncol
April 2023
Department of Medicine, CHU de Québec-Université Laval, Quebec City, QC G1J 1Z4, Canada.
The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents. Among them are Bruton's tyrosine kinase (BTK) inhibitors, which have demonstrated excellent efficacy in indolent B-cell NHLs and CLL. Although BTK inhibitors are generally thought to be more tolerable than chemoimmunotherapy, they are associated with a unique safety profile including varying rates of rash, diarrhea, musculoskeletal events, cardiovascular events, and bleeding.
View Article and Find Full Text PDFPicomolar zinc binding modulates formation of Bcl10-nucleating assemblies of the caspase recruitment domain (CARD) of CARD9.
J Biol Chem
October 2018
From the Early Discovery Biochemistry Department and
The caspase recruitment domain-containing protein 9 (CARD9)-B-cell lymphoma/leukemia 10 (Bcl10) signaling axis is activated in myeloid cells during the innate immune response to a variety of diverse pathogens. This signaling pathway requires a critical caspase recruitment domain (CARD)-CARD interaction between CARD9 and Bcl10 that promotes downstream activation of factors, including NF-κB and the mitogen-activated protein kinase (MAPK) p38. Despite these insights, CARD9 remains structurally uncharacterized, and little mechanistic understanding of its regulation exists.
View Article and Find Full Text PDFLenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Eur J Haematol
July 2018
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Objectives: We previously showed that immunization with ex vivo- generated autologous dendritic cells loaded with apoptotic tumor cells (Apo-DC) potentiated tumor-specific immunity in chronic lymphocytic leukemia (CLL) patients. Here, we evaluated safety and immunogenicity of Apo-DC in combination with lenalidomide, granulocyte-macrophage colony-stimulating factor (GM-CSF), and low-dose cyclophosphamide (CTX).
Methods: Ten previously untreated patients with slowly progressing CLL received 5 Apo-DC vaccinations and lenalidomide orally for 24 weeks either alone (cohort I, n = 5) or together with subcutaneous GM-CSF and intravenous CTX (cohort II, n = 5).
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.
Cancer Immunol Immunother
June 2012
Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden.
We previously demonstrated that autologous dendritic cells that have endocytosed apoptotic bodies of chronic lymphocytic leukemia (CLL) cells (Apo-DC) can stimulate antileukemic T cell responses in vitro. In this phase I study, we vaccinated 15 asymptomatic CLL patients at five time points with Apo-DC administered intradermally either alone (cohort I), or in combination with subcutaneous granulocyte-macrophage-colony-stimulating-factor (GM-CSF) (cohort II) or with GM-CSF and intravenous low-dose cyclophosphamide (cohort III). Aim of the study was to evaluate the safety and immunogenicity of Apo-DC alone or in combination with GM-CSF and low-dose cyclophosphamide in CLL patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!